Axillary Lymph Nodes
Researchers investigated the incidence of lymphedema on patients with breast cancer treated with TAC after axillary lymph node dissection (ALND), with or without radiotherapy, and its impact on quality of life for patients.
"Routine use of ALND should be abandoned." That's the conclusion based on 10-year survival data from the ACOSOG Z0011 randomized study comparing sentinel lymph node dissection alone to ALND in women with clinical T1-2 N0 M0 breast cancer and a positive sentinel node presented at the 2016 ASCO Annual Meeting.
The accuracy of axillary staging and of pathologic evaluation of clinically node-positive breast cancer is improved by a new procedure, reducing the need for a more invasive procedure with debilitating complications.
Sentinel lymph node surgery was associated with a false-negative rate higher than a prespecified threshold in women who underwent chemotherapy after initially presenting with biopsy-proven breast cancer in movable axillary lymph nodes.
Removal of all axillary lymph nodes may be unnecessary in women undergoing breast-conserving therapy (partial mastectomy followed by whole-breast radiation), researchers have found.
Both axillary lymph node dissection and axillary radiotherapy provide excellent regional control for breast cancer patients with a positive sentinel node biopsy, according to a final study analysis.
MALND, en endoscopic technique to determine if breast cancer has spread to the adjoining lymph nodes, can reduce the complications associated with the conventional surgical approach to axillary lymph node dissection.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|